Detalhe da pesquisa
1.
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
J Med Genet
; 2023 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37940383
2.
Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study.
Mol Genet Metab
; 131(1-2): 219-228, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33012654
3.
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
N Engl J Med
; 375(6): 545-55, 2016 Aug 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27509102
4.
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
J Med Genet
; 54(4): 288-296, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27834756
5.
Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).
Adv Ther
; 39(5): 2109-2127, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35296993
6.
Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.
Am J Transl Res
; 11(3): 1683-1696, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30972193
7.
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.
JIMD Rep
; 25: 95-106, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26303609
8.
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa.
JIMD Rep
; 23: 7-15, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25822820
9.
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
Neuromuscul Disord
; 25(4): 321-32, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25617983